Transthyretin sequesters amyloid beta protein and prevents amyloid formation.

Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56

Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest (2000) 5.07

Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A (1995) 3.36

The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A (2002) 2.74

The toxicity in vitro of beta-amyloid protein. Biochem J (1995) 2.17

Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 2.09

The choroid plexus removes beta-amyloid from brain cerebrospinal fluid. Exp Biol Med (Maywood) (2005) 1.97

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A (1996) 1.87

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis (2010) 1.86

Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem J (1995) 1.72

Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A (2008) 1.64

Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochem J (1996) 1.61

Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener (2011) 1.58

Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. Proc Natl Acad Sci U S A (2010) 1.38

Biomarkers of Alzheimer's disease. Neurobiol Dis (2008) 1.37

NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proc Natl Acad Sci U S A (1995) 1.32

Evidence for defective retinoid transport and function in late onset Alzheimer's disease. Proc Natl Acad Sci U S A (2003) 1.23

Enhanced cognitive activity--over and above social or physical activity--is required to protect Alzheimer's mice against cognitive impairment, reduce Abeta deposition, and increase synaptic immunoreactivity. Neurobiol Learn Mem (2007) 1.22

Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. Proc Natl Acad Sci U S A (2004) 1.20

Blood-brain-barriers in aging and in Alzheimer's disease. Mol Neurodegener (2013) 1.17

Gender, sex steroid hormones, and Alzheimer's disease. Horm Behav (2012) 1.14

Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid. Proc Natl Acad Sci U S A (2007) 1.11

Amyloid oligomer conformation in a group of natively folded proteins. PLoS One (2008) 1.10

Neurotoxicology of the brain barrier system: new implications. J Toxicol Clin Toxicol (2001) 1.09

APP physiological and pathophysiological functions: insights from animal models. Cell Res (2011) 1.03

DHA may prevent age-related dementia. J Nutr (2010) 1.02

O-GlcNAc cycling mutants modulate proteotoxicity in Caenorhabditis elegans models of human neurodegenerative diseases. Proc Natl Acad Sci U S A (2012) 1.00

Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease? Mol Neurodegener (2011) 0.99

Plug-based microfluidics with defined surface chemistry to miniaturize and control aggregation of amyloidogenic peptides. Angew Chem Int Ed Engl (2009) 0.97

Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor. PLoS One (2008) 0.97

Characterization of the interaction of β-amyloid with transthyretin monomers and tetramers. Biochemistry (2010) 0.95

Cystatin C in Alzheimer's disease. Front Mol Neurosci (2012) 0.94

Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's Disease. Front Aging Neurosci (2013) 0.94

BMP4 sufficiency to induce choroid plexus epithelial fate from embryonic stem cell-derived neuroepithelial progenitors. J Neurosci (2012) 0.93

Modification by docosahexaenoic acid of age-induced alterations in gene expression and molecular composition of rat brain phospholipids. Proc Natl Acad Sci U S A (2003) 0.93

Towards retinoid therapy for Alzheimer's disease. Curr Alzheimer Res (2009) 0.92

Mechanisms of transthyretin inhibition of β-amyloid aggregation in vitro. J Neurosci (2013) 0.91

Metallothionein and brain inflammation. J Biol Inorg Chem (2011) 0.90

17beta-estradiol induces transthyretin expression in murine choroid plexus via an oestrogen receptor dependent pathway. Cell Mol Neurobiol (2009) 0.90

Macromolecules involved in production and metabolism of beta-amyloid at the brain barriers. Brain Res (2007) 0.90

Transthyretin as both a sensor and a scavenger of β-amyloid oligomers. Biochemistry (2013) 0.88

Association of TTR polymorphisms with hippocampal atrophy in Alzheimer disease families. Neurobiol Aging (2009) 0.86

Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimer's disease. Mol Neurodegener (2014) 0.85

Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. PLoS One (2012) 0.83

Chaperones in Neurodegeneration. J Neurosci (2015) 0.83

Complexes of amyloid-beta and cystatin C in the human central nervous system. J Alzheimers Dis (2009) 0.83

The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme: a biological perspective. Prion (2008) 0.83

Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. J Lipid Res (2015) 0.82

Differential modification of Cys10 alters transthyretin's effect on beta-amyloid aggregation and toxicity. Protein Eng Des Sel (2009) 0.82

Identification and characterization of Aβ peptide interactors in Alzheimer's disease by structural approaches. Front Aging Neurosci (2014) 0.81

Regulating extracellular proteostasis capacity through the unfolded protein response. Prion (2015) 0.80

Time-dependent changes in gene expression induced by secreted amyloid precursor protein-alpha in the rat hippocampus. BMC Genomics (2013) 0.79

Central transthyretin acts to decrease food intake and body weight. Sci Rep (2016) 0.78

Effective screen for amyloid β aggregation inhibitor using amyloid β-conjugated gold nanoparticles. Int J Nanomedicine (2010) 0.78

Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline. Alzheimers Dement (Amst) (2015) 0.78

Neuronal life span versus health span: principles of natural selection at work in the degenerating brain. J Mol Neurosci (2011) 0.77

The effect of aging on brain barriers and the consequences for Alzheimer's disease development. Mamm Genome (2016) 0.77

Transthyretin participates in beta-amyloid transport from the brain to the liver- involvement of the low-density lipoprotein receptor-related protein 1? Sci Rep (2016) 0.77

Chronic lithium administration down regulates transthyretin mRNA expression in rat choroid plexus. Neuropsychiatr Dis Treat (2006) 0.77

Stability of the transthyretin molecule as a key factor in the interaction with a-beta peptide--relevance in Alzheimer's disease. PLoS One (2012) 0.77

Cystatin C in aging and in Alzheimer's disease. Ageing Res Rev (2016) 0.75

IgG Conformer's Binding to Amyloidogenic Aggregates. PLoS One (2015) 0.75

Transthyretin and BRICHOS: The Paradox of Amyloidogenic Proteins with Anti-Amyloidogenic Activity for Aβ in the Central Nervous System. Front Neurosci (2017) 0.75

Resveratrol administration increases Transthyretin protein levels ameliorating AD features - importance of transthyretin tetrameric stability. Mol Med (2016) 0.75

Transthyretin variants with improved inhibition of β-amyloid aggregation. Protein Eng Des Sel (2016) 0.75

Is Transthyretin a Regulator of Ubc9 SUMOylation? PLoS One (2016) 0.75

Peptides Composed of Alternating L- and D-Amino Acids Inhibit Amyloidogenesis in Three Distinct Amyloid Systems Independent of Sequence. J Mol Biol (2016) 0.75

Sortilin Fragments Deposit at Senile Plaques in Human Cerebrum. Front Neuroanat (2017) 0.75

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32

Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell (1993) 10.15

The molecular pathology of Alzheimer's disease. Neuron (1991) 8.21

Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci (1993) 7.92

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature (1992) 7.02

Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science (1990) 6.03

Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 5.68

Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science (1992) 5.22

Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 4.86

Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem (1992) 4.66

Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J Mol Biol (1978) 4.47

beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci (1992) 4.10

Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem (1987) 3.04

The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J (1993) 2.66

Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J Virol (1991) 2.47

Human amyloidosis, Alzheimer disease and related disorders. Lab Invest (1988) 2.44

In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer's disease beta-protein. Biochem Biophys Res Commun (1986) 2.16

Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron (1990) 2.09

Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem Biophys Res Commun (1992) 1.85

Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem Biophys Res Commun (1993) 1.80

In situ hybridization of nucleus basalis neurons shows increased beta-amyloid mRNA in Alzheimer disease. Proc Natl Acad Sci U S A (1988) 1.51

Isolation and characterization of apolipoprotein E. Methods Enzymol (1986) 1.39

SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol (1992) 1.30

Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun (1994) 1.27

Beta-amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease. Brain Res (1992) 1.16

Sequestration of amyloid beta-peptide. Ann N Y Acad Sci (1993) 1.13

Alzheimer disease and the prion disorders amyloid beta-protein and prion protein amyloidoses. Proc Natl Acad Sci U S A (1993) 1.08

Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci U S A (1992) 1.07

Solution structure of residues 1-28 of the amyloid beta-peptide. Biochemistry (1994) 1.06

Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer's disease. Acta Neurol Scand (1988) 1.02

Serum amyloid A protein, albumin and prealbumin in Alzheimer's disease and in demented patients with Down's syndrome. Acta Neurol Scand (1986) 0.89

Production and functional analysis of normal and variant recombinant human transthyretin proteins. J Biol Chem (1992) 0.88

Avid binding of beta A amyloid peptide to its own precursor. Exp Neurol (1993) 0.81

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32

Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology (1993) 14.54

Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet (1994) 7.07

Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 5.68

Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 4.86

Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res (1984) 4.12

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology (2002) 3.73

Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet (1996) 3.58

Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J Biol Chem (1978) 3.57

Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science (1991) 3.42

The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 3.21

Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem (1987) 3.04

Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology (2003) 3.03

Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem (1981) 3.02

Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science (1994) 2.98

Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology (1995) 2.90

Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins. J Biol Chem (1977) 2.86

Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci (2001) 2.82

Expression of apolipoprotein E during nerve degeneration and regeneration. Proc Natl Acad Sci U S A (1986) 2.80

A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest (1989) 2.71

Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem (1982) 2.71

Human apolipoprotein E. The complete amino acid sequence. J Biol Chem (1982) 2.64

Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci U S A (1989) 2.48

Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem (1990) 2.42

A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry (1994) 2.41

Invited article: The ABPN maintenance of certification program for neurologists: past, present, and future. Neurology (2008) 2.31

A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest (1980) 2.27

Two independent lipoprotein receptors on hepatic membranes of dog, swine, and man. Apo-B,E and apo-E receptors. J Clin Invest (1981) 2.27

Recombinant human interleukin 1 alpha: purification and biological characterization. J Immunol (1986) 2.24

Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med (1996) 2.19

Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A (1995) 2.11

"You are what you eat": diet modifies cuticular hydrocarbons and nestmate recognition in the Argentine ant, Linepithema humile. Naturwissenschaften (2000) 2.06

Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J Biol Chem (1996) 2.06

Characterization of antimicrobial resistance in enterococci of animal origin. Antimicrob Agents Chemother (1995) 2.05

Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem (1994) 2.04

beta-Adrenergic receptor agonists increase phospholipid methylation, membrane fluidity, and beta-adrenergic receptor-adenylate cyclase coupling. Proc Natl Acad Sci U S A (1979) 2.04

Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging (2006) 2.03

Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. Biochemistry (2000) 2.01

Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res (1982) 2.01

Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci U S A (1982) 1.96

Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci U S A (1987) 1.93

Canine lipoproteins and atherosclerosis. II. Characterization of the plasma lipoproteins associated with atherogenic and nonatherogenic hyperlipidemia. Circ Res (1974) 1.91

Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res (1990) 1.90

What public school teachers teach about preventing pregnancy, AIDS and sexually transmitted diseases. Fam Plann Perspect (1989) 1.88

The bacterially expressed yeast CDC34 gene product can undergo autoubiquitination to form a multiubiquitin chain-linked protein. J Biol Chem (1993) 1.86

Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol (1994) 1.84

Subfractionation of human high density lipoproteins by heparin-Sepharose affinity chromatography. J Lipid Res (1980) 1.84

Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin Infect Dis (2000) 1.82

Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol (2006) 1.78

Reactive Lyme serology in optic neuritis. J Neuroophthalmol (2005) 1.76

Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades. FASEB J (2001) 1.75

The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments. J Biol Chem (1983) 1.75

Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A (1994) 1.74

Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem (1988) 1.72

Clinical application of apolipoprotein E genotyping to Alzheimer's disease. Lancet (1994) 1.71

Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience (2010) 1.70

Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci (1998) 1.69

The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. J Biol Chem (1983) 1.67

Borrelia burgdorferi-specific immune complexes in acute Lyme disease. JAMA (1999) 1.64

Affective instability and impulsivity in borderline personality and bipolar II disorders: similarities and differences. J Psychiatr Res (2001) 1.62

Apoprotein (E--A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction. J Biol Chem (1978) 1.60

Canine hyperlipoproteinemia and atherosclerosis. Accumulation of lipid by aortic medial cells in vivo and in vitro. Am J Pathol (1977) 1.60

Inhibition of receptor-mediated clearance of lysine and arginine-modified lipoproteins from the plasma of rats and monkeys. Proc Natl Acad Sci U S A (1980) 1.59

Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J Biol Chem (1988) 1.57

Cognitive functioning in late Lyme borreliosis. Arch Neurol (1991) 1.54

Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest (1994) 1.54

A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology (1997) 1.54

Sequestration of antibody to Borrelia burgdorferi in immune complexes in seronegative Lyme disease. Lancet (1990) 1.52

Apoprotein (E--A-II) complex of human plasma lipoproteins. II. Receptor binding activity of a high density lipoprotein subfraction modulated by the apo(E--A-II) complex. J Biol Chem (1978) 1.52

Phospholipid methylation unmasks cryptic beta-adrenergic receptors in rat reticulocytes. Science (1979) 1.51

Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. Proc Natl Acad Sci U S A (2001) 1.51

The effect of Tn916 insertions on contour-clamped homogeneous electrophoresis patterns of Enterococcus faecalis. J Clin Microbiol (1997) 1.51

Swine lipoproteins and atherosclerosis. Changes in the plasma lipoproteins and apoproteins induced by cholesterol feeding. Biochemistry (1975) 1.50

A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler (1999) 1.50

Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J Biol Chem (1986) 1.50

Early and specific antibody response to OspA in Lyme Disease. J Clin Invest (1994) 1.50

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 1.49

Survey of training programs' means for promoting neurology and attracting trainees. Neurology (2006) 1.49

Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. Ann Thorac Surg (1997) 1.48

Cytogenetic and flow cytometric analysis of a pancreatoblastoma. Cancer Genet Cytogenet (1995) 1.48

Accelerated clearance of low-density and high-density lipoproteins and retarded clearance of E apoprotein-containing lipoproteins from the plasma of rats after modification of lysine residues. Proc Natl Acad Sci U S A (1979) 1.48

In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants. Biochemistry (2000) 1.46

Hypocholesterolaemic effects of lovastatin in familial defective apolipoprotein B-100. Lancet (1992) 1.46

Canine lipoproteins and atherosclerosis. I. Isolation and characterization of plasma lipoproteins from control dogs. Circ Res (1974) 1.44

Barriers to contraceptive services. Fam Plann Perspect (1987) 1.43

The isolation of ecdysterone inducible genes by hybridization subtraction chromatography. Nucleic Acids Res (1981) 1.43

Seronegative chronic relapsing neuroborreliosis. Eur Neurol (1995) 1.43

Linkage analysis for autism in a subset families with obsessive-compulsive behaviors: evidence for an autism susceptibility gene on chromosome 1 and further support for susceptibility genes on chromosome 6 and 19. Mol Psychiatry (2004) 1.41

Shape and size of the corpus callosum in schizophrenia and schizotypal personality disorder. Schizophr Res (2000) 1.41

Apolipoprotein E in Creutzfeldt-Jacob disease. Lancet (1995) 1.41

Isolation and characterization of apolipoprotein E. Methods Enzymol (1986) 1.39

Cerebrospinal fluid findings in children with Lyme disease-associated facial nerve palsy. Arch Pediatr Adolesc Med (1997) 1.39

HIV infection in the blood donors of Delhi, India: 1 1/2 years' experience. J Acquir Immune Defic Syndr (1991) 1.39

Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53. J Biol Chem (2000) 1.36

Intravenous infusion of apolipoprotein E accelerates clearance of plasma lipoproteins in rabbits. J Clin Invest (1989) 1.35

Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem (1994) 1.34

Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization. J Biol Chem (1993) 1.33

Interaction of plasma lipoproteins containing apolipoproteins B and E with heparin and cell surface receptors. Biochim Biophys Acta (1979) 1.33

Human apolipoprotein B-100 heparin-binding sites. J Biol Chem (1987) 1.32

Lipid binding-induced conformational change in human apolipoprotein E. Evidence for two lipid-bound states on spherical particles. J Biol Chem (2001) 1.31